The growth of Urofollitropin sales in my country is closely related to the
birth status of the population. In recent years, the growth rate of the number
of births in my country has fluctuated from year to year. In 2014, the number of
births in my country was 16.87 million, an increase of 2.87% year-on-year; in
2015, the number of births was 16.55 million, a year-on-year decrease of 1.9%;
The number of people decreased by 3.53% year-on-year. Correspondingly, the sales
growth rate of follicle-stimulating hormone in sample hospitals in my country
fluctuates with the growth rate of the birth population.
In the years when the
growth rate of the birth population was slow or negative (2015 and 2017), the
sales of follicle stimulation in sample hospitals in my country only grew at a
low speed. It can be seen that there is a relationship between the sales of
follicle-stimulating hormones and the number of births in the same direction. In
the first half of 2018, the sales of follicle-stimulating hormones in sample
hospitals in my country increased by 6.22% year-on-year. In the short term, the
period of rapid growth in the number of newborns brought about by the
comprehensive two-child policy has passed; in the long run, the change in
people's concept of fertility will lead to a slow and steady increase in the
number of births in the future, and the growth rate of follicle-stimulating
hormone may remain stable.
The above is the relevant content summarized by the editor of Kangyuan
Company. If you want to know more, please continue to follow us. We will
regularly update you about Human chorionic gonadotropin, Human Menopausal
Gonadotropin supplier, Urofollitropin price, Urokinase manufacturer, and Hormone
API Manufacturer Related content, I hope to help you.